Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?

By Gerber Bernd  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 613-624

Springer Publishing Company

Access to resources Recommend Favorite

Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”

By Koolen Bas   Wesseling Jelle  

Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. : 700-700

Springer Publishing Company

Access to resources Recommend Favorite

Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla

By Koolen Bas   Valdés Olmos Renato   Wesseling Jelle   Vogel Wouter   Vincent Andrew   Gilhuijs Kenneth   Rodenhuis Sjoerd   Rutgers Emiel   Vrancken Peeters Marie-Jeanne  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2227-2235

Springer Publishing Company

Access to resources Recommend Favorite

Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on “Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)”

By Chao Wan-Ru   Han Chih-Ping  

Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. : 699-699

Springer Publishing Company

Access to resources Recommend Favorite

Duration of Chemotherapy for Early Stage Breast Cancer: Have We Reached the Limit? What is the Survival Impact of Amenorrhea?

By Hirsh Rebecca  

Current Treatment Options in Oncology, Vol. 11, Iss. 3-4, 2010-12 ,pp. : 59-62

Springer Publishing Company

Access to resources Recommend Favorite